RecruitingPhase 1NCT07021547

A Study of LY3867070 in Healthy Participants

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3867070 in Healthy Participants

Sponsor

Eli Lilly and Company

Enrollment

196 participants

Start Date

May 27, 2025

Study Type

INTERVENTIONAL

Conditions

Healthy

Summary

The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria3

Are overtly healthy as determined by medical evaluation
Part C of the study includes only Japanese and Chinese participants
Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive

Exclusion Criteria6

Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy
Have a significant history or current thyroid disease
Have a significant history of or current psychiatric disorders, rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome and hyperaldosteronism), hematological, or neurological disorders
Are smokers (including electronic cigarettes) within 6 months prior to screening and unwilling to refrain from smoking for the duration of the study.
Unwilling to undergo skin biopsies (for Part B only)
Are unwilling to have body hair cut or shaved in cases where hair, in the investigator's opinion, could interfere with noninvasive skin patch